Chemical Property of CNTO 148
Chemical Property:
- Purity/Quality:
-
97% *data from raw suppliers
GOLIMUMAB 95.00% *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
Useful:
-
Description
The proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) has
been implicated as the primary mediator of articular inflammation in
diseases such as RA, PsA, and AS. Targeting TNF-a has been a successful
strategy in the intervention of a range of immunoinflammatory disorders.
Biologics have risen to the forefront of TNF-α blockade with infliximab, a
chimeric monoclonal antibody (mAb), and etanercept, a fusion protein
comprised of the ligand-binding segment of the soluble TNF receptor,
reaching the market in the late 1990s for the initial indication of RA. Since
then, their use has expanded to other diseases of inflammatory etiology,
and two additional TNF-α inhibitors have joined the competition.
Golimumab, a
human anti-TNF-α mAb that binds to both soluble and transmembrane
forms of TNF-a, is the first once-monthly subcutaneous agent to enter the
market and is currently approved for the treatment of RA in combination
with methotrexate (MTX), PsA alone or in combination with MTX, and AS.
.
-
Uses
Treatment of allergic asthma.
